DexCom, Inc. (NASDAQ:DXCM) EVP Jereme M. Sylvain Sells 7,000 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jereme M. Sylvain sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This represents a 4.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

DexCom Trading Down 0.7 %

NASDAQ DXCM opened at $70.26 on Wednesday. The firm’s 50 day moving average price is $84.53 and its two-hundred day moving average price is $76.98. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market cap of $27.46 billion, a price-to-earnings ratio of 49.13, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Hedge Funds Weigh In On DexCom

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in DexCom by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company’s stock valued at $775,256,000 after purchasing an additional 56,094 shares in the last quarter. Jennison Associates LLC raised its position in shares of DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after buying an additional 710,858 shares in the last quarter. Norges Bank bought a new stake in shares of DexCom during the 4th quarter valued at approximately $385,367,000. Northern Trust Corp grew its holdings in DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company’s stock worth $322,454,000 after acquiring an additional 753,857 shares during the last quarter. Finally, Groupama Asset Managment boosted its stake in shares of DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after purchasing an additional 31,358 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on DXCM shares. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.